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Summary
Background: Clopidogrel has been utilized as an antiplatelet therapy for patients undergoing
stent implantation. In the Japanese population, however, the impact of clopidogrel on the
occurrence of early adverse events is unknown. This study sought to evaluate procedural major
bleeding and myocardial infarction in patients undergoing stent implantation with adjunctive
clopidogrel compared with ticlopidine.
Methods and results: The retrospective analysis included 311 patients who had stent implan-
tation between January 2007 and April 2009. The patients were divided into groups with
clopidogrel (n = 159) and ticlopidine (n = 152). Primary endpoint was major bleeding and myocar-
dial infarction at 30 days. The incidence of major bleeding was 4.4% in the clopidogrel
group vs. 3.9% in the ticlopidine group (p = 0.94). The incidence of myocardial infarction
was 3.8% in the clopidogrel group vs. 7.9% in the ticlopidine group (p = 0.19). In patients
with unstable angina, however, there was a strong trend toward lower incidence of myocar-
dial infarction in patients treated with clopidogrel than those treated with ticlopidine (4.1%
vs. 13.3%, p = 0.08). The incidence of major bleeding was no different (1.4% vs. 5.3%,
p = 0.37).
Conclusions: In patients with unstable angina and emergent coronary intervention, adjunctive
clopidogrel therapy may have a slight positive impact on the prevention of myocardial infarction
without increasing the risk of bleeding complications.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Introduction
With the widespread use of percutaneous coronary inter-
vention (PCI) in patients with coronary artery disease,
an aggressive antithrombotic and antiplatelet treatment
strategy has been necessary to reduce the incidence of
thrombotic events [1,2]. Contrary to the beneﬁt, it also
has a negative proﬁle that might increase the risk of
hemorrhagic complications [3,4]. An ideal antithrombotic
regimen is one that could reduce the risk of thrombotic
events more and simultaneously minimize the risk of hemor-
rhagic complications. Dual antiplatelet therapy with aspirin
plus thienopyridines is an essential strategy for preven-
tion of recurrent ischemic events in patients undergoing
coronary stent implantation [5]. Although thienopyridines,
both ticlopidine and clopidogrel, act by blocking one of
the three adenosine 5′-diphosphate receptors, clopidogrel
has the advantage of a more rapid onset of action com-
pared with ticlopidine, particularly in patients who had a
300-mg loading dose of clopidogrel [6,7]. Since the use
of clopidogrel was approved for Japanese patients with
stroke and acute coronary syndromes, it has been utilized
as a standard antiplatelet therapy for patients undergo-
ing stent implantation. However, there is concern about
bleeding complications following clopidogrel administra-
tion in the Japanese population, because Japanese patients
have been traditionally treated with ticlopidine of lower
dose as compared the loading and maintenance doses
of ticlopidine in western countries. In daily practice of
Japanese patients, therefore, the impact of clopidogrel
on the occurrence of early adverse events is unknown.
This study sought to evaluate procedural major bleed-
ing and myocardial infarction in patients undergoing stent
implantation with adjunctive clopidogrel compared with
ticlopidine.
Methods
Patient population
This analysis comprised only patients undergoing the ﬁrst
PCI at our hospital between January 2007 and April 2009,
excluding patients with warfarin treatment, with in-stent
restenosis or acute myocardial infarction, or cardiogenic
shock before procedure. Finally, we found a total of 311
patients who had successful stent implantation having com-
bined antiplatelet regimens of aspirin plus ticlopidine or
clopidogrel. The database showed that ticlopidine was used
in the early period whereas clopidogrel was used more
recently since October 2007.
Antiplatelet therapy
All patients were treated with aspirin plus ticlopidine or
clopidogrel. Patients planning PCI were given 75mg clopi-
dogrel or 200mg ticlopidine at least 3 days before the
procedure. In cases of unstable angina pectoris or urgent
PCI within 48 h after admission, clopidogrel loading dose of
300mg was given before the procedure whereas ticlopidine
was given at the normal dose (200mg) before procedure
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r immediately after procedure. A heparin bolus (100U/kg)
as administered before the procedure, with a repeat bolus
f 5000U given as needed to maintain an activated clotting
ime of ≥250 s throughout the procedure. Post-procedural
herapy included daily 100mg aspirin indeﬁnitely, and 75mg
lopidogrel or 200mg ticlopidine per day for at least 12
onths and other cardiac medications prescribed by the
atient’s physician.
tent and post-procedural management
rug-eluting stents of either sirolimus or paclitaxel were
sed in our hospital if not contraindicated, for exam-
le patients with planned surgical operations or with
alignancies. Target lesions were predilatated with con-
entional angioplasty balloons; after stent implantation,
igh-pressure balloon inﬂation was performed to achieve
satisfactory angiographic result of less than 25% residual
tenosis by visual estimate.
eﬁnitions and follow-up
he primary endpoint of the study was the incidences
f major bleeding and myocardial infarction at 30 days,
espectively. The secondary endpoint of the study was the
ombined incidence of cardiac death, myocardial infarc-
ion, urgent target vessel revascularization (coronary bypass
urgery or PCI) due to myocardial infarction, and major
leeding within 30 days after procedure (this quadruple
ndpoint aimed at measuring the risk of both ischemic
nd bleeding complications, also known as ‘‘net clini-
al beneﬁt’’) [8]. Major bleeding was deﬁned according
o the criteria used in the Randomized Evaluation in PCI
inking Angiomax to Reduced Clinical Events (REPLACE-2)
rial [3]: intracranial, intraocular, or retroperitoneal hem-
rrhage, clinically overt blood loss resulting in a decrease
n hemoglobin of more than 3 g per deciliter, any decrease
n hemoglobin of more than 4 g per deciliter, or transfu-
ion of 2 or more units of packed red blood cells or whole
lood. The deﬁnition of myocardial infarction included the
evelopment of pathologic Q waves (≥30ms in duration and
0.1mV in depth) in ≥2 contiguous precordial leads or ≥2
djacent limb leads, or elevation of creatine kinase (CK)
B isoenzyme (or total CK if CK-MB not available) ≥2 times
he upper limit of normal [8]. Follow-up was obtained in all
atients at 30 days. Patients who had cardiac complaints
nderwent a complete clinical, electrocardiographic, and
aboratory evaluation.
tatistical analysis
he data are presented as mean± SD or counts (%). Cat-
gorical data were compared with the chi-squared test
r Fisher’s exact test when cell values were less than
. Continuous data were compared using a two-tailed
npaired t test. Survival analysis was performed by applying
he Kaplan—Meier method. Differences in the cumulative
dverse cardiac event rates were assessed with the log-rank
est, which allowed the calculation of odds ratio [OR]
95% conﬁdence intervals [CI]) associated with clopidogrel
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roup. A probability value <0.05 was considered to indicate
tatistical signiﬁcance.
esults
he mean age of the patients was 69 years, 28% of them were
omen, 39% had diabetes mellitus, and 37% of patients had
nstable angina pectoris. Most patients (88%) were treated
ith drug-eluting stents, and 12% of patients were treated
ith bare-metal stents. The total of 311 patients were
ivided into groups with clopidogrel (n = 159) and ticlopidine
n = 152).
Baseline characteristics of patients are shown in Table 1.
he groups were not different with respect to baseline clini-
al characteristics. Similarly, baseline lesion characteristics
ere well matched, including the distribution of culprit
rtery sites and type B2/C lesions, and the thrombolysis in
yocardial infarction (TIMI) ﬂow grades at initial angiogra-
hy. The results of quantitative coronary angiography did
ot signiﬁcantly differ between the 2 groups (Table 2).
onversely, differences were seen regarding the procedural
ariables. In the clopidogrel group, the use of paclitaxel-
luting stent was signiﬁcantly higher than in the ticlopidine
roup. Patients in the ticlopidine group had a higher fre-
uency of the sirolimus-eluting stent and a longer stent
ength. Table 3 shows a cumulative frequency of clinical
utcomes at 30 days. There were 2 deaths in the ticlo-
idine group. Myocardial infarction occurred in 6 of 159
atients (3.8%) in the clopidogrel group vs. 12 of 152 patients
7.9%) in the ticlopidine group (OR = 0.46, 95% CI 0.14—1.36,
= 0.19). The incidence of major bleeding was seen in
patients (4.4%) of clopidogrel group and in 6 patients
3.9%) of ticlopidine group (OR = 1.12, 95% CI 0.31—4.14,
= 0.94). Stent thrombosis occurred in 1 patient in both
roups, respectively. The secondary endpoint of the study,
he composite of death, myocardial infarction, urgent target
essel revascularization, or major bleeding was encoun-
ered in 13 patients (8.2%) of the clopidogrel group and 18
atients (11.8%) in the ticlopidine group (OR = 0.66, 95% CI
P
s
ﬁ
t
m
Table 1 Baseline characteristics.
Characteristic Clopidogrel (n
Age, years 68 ± 10
Women, n 26 (16)
Body weight, kg 63.1± 11.5
Body mass index, kg/m2 23.5± 3.4
Diabetes, n 58 (36)
Hypertension, n 129 (81)
Hypercholesteremia, n 100 (63)
Prior myocardial infarction, n 30 (19)
Prior coronary artery bypass surgery 10 (6)
Hemoglobin, g/dl 13.4± 2.1
Clinical presentation
Stable angina, n 100 (63)
Unstable angina, n 59 (37)
Left ventricular ejection fraction, % 65 ± 12
Multivessel disease 85 (53)
Data are presented as number of patients (%) or mean± SD.F. Hayashi et al.
.29—1.50, p = 0.37). Speciﬁc subgroup analyses were also
erformed among 149 patients with unstable angina pec-
oris or urgent PCI. Of these, 74 patients were treated with
loading dose of 300mg clopidogrel before procedures.
eventy-ﬁve patients were treated with 200mg ticlopidine
efore procedure or immediately after procedure. In both
roups, there were no signiﬁcant differences in clinical and
ngiographic characteristics including age (p = 0.22), dia-
etes (p = 0.32), multivessel disease (p = 0.33), B2/C lesions
p = 0.95), left ventricular ejection fraction (p = 0.72), pre-
inimal lumen diameter (p = 0.56), lesion length (p = 0.56),
ost-TIMI ﬂow grade (p = 0.78), and stent length (p = 0.43).
owever, patients in the ticlopidine group had a tendency
oward a higher frequency of women (12.2% vs. 24.0%,
= 0.09) and a higher pre-TIMI ﬂow grade (2.3% vs. 2.6%,
= 0.08). The incidence of myocardial infarction was 4.1%
n the clopidogrel group and 13.3% in the ticlopidine group
p = 0.08). Of the patients, no-reﬂow phenomenon was seen
n 1 case in the clopidogrel group. Whereas side branch
cclusion in 2 cases, distal embolization in 2 cases and no-
eﬂow in 1 case were observed in the ticlopidine group.
ig. 1 shows that the cumulative event curves for clopidogrel
nd ticlopidine groups were diverging during the ﬁrst 2 days
fter the procedure. On the other hand, there was no sig-
iﬁcant difference in terms of major bleeding between the
lopidogrel and ticlopidine groups (1.4% vs. 5.3%, p = 0.37).
iscussion
he present study assessed the safety and efﬁcacy outcomes
f replacing ticlopidine with clopidogrel in patients under-
oing stent implantation, and the current series represents
broad range of patients with coronary artery disease
rom low-to-moderate risk patients undergoing elective
CI to high-risk non-ST-segment elevation acute coronary
yndromes, broadly reﬂecting clinical practice. The main
ndings of this analysis are: (1) in daily practice in Japan,
here were no signiﬁcant differences in the incidence of
ajor bleeding and myocardial infarction between the
= 159) Ticlopidine (n = 152) p
69 ± 9 0.25
30 (20) 0.53
63.4± 13.6 0.82
24.1± 4.0 0.17
65 (43) 0.31
114 (75) 0.24
88 (58) 0.43
29 (19) 0.96
13 (9) 0.45
13.2± 1.9 0.37
95 (62.5) 0.97
57 (37.5)
64 ± 14 0.75
77 (51) 0.70
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Table 2 Lesion and procedural characteristics.
Characteristic Clopidogrel (n = 159) Ticlopidine (n = 152) p
Target coronary artery
Left anterior descending 85 (53.0) 80 (52.6) 0.41
Right coronary artery 39 (24.5) 35 (23.0)
Left circumﬂex 21 (13.2) 18 (12.0)
Left main artery 13 (8.0) 17 (11.2)
Bypass graft 2 (1.3) 2 (1.3)
ACC/AHA classiﬁcation
Type B2/C lesions 110 (69) 103 (68) 0.88
TIMI ﬂow grade before intervention 0.24
0 27 (17) 14 (9)
1 2 (1.3) 3 (2)
2 11 (7) 12 (8)
3 119 (74.7) 123 (81)
TIMI ﬂow grade after intervention
2 2 (1) 1 (1) 0.97
3 157 (99) 151 (99)
Quantitative coronary angiogram
Vessel size, mm 2.78± 0.58 2.85± 0.41 0.50
MLD before intervention, mm 0.86± 0.35 0.88± 0.33 0.73
Diameter stenosis, % 68.6± 10.6 66.9± 13.8 0.85
Lesion length, mm 19.8± 23.5 18.1± 13.2 0.47
MLD after intervention, mm 2.60± 0.51 2.68± 0.40 0.29
Diameter stenosis after intervention, % 13.3± 6.6 12.4± 6.8 0.48
Type of interventions 0.98
Bare-metal stent 19 (12) 19 (12.5)
Drug-eluting stent, n 140 (88) 133 (87.5)
Sirolimus-eluting stent, n 39 (27.9) 78 (58.6) <0.001
Paclitaxel-eluting stent, n 101 (72.1) 55 (41.4)
Stent length, mm 33 ± 18 37 ± 20 0.07
ACC/AHA indicates American College of Cardiology/American Heart Association; TIMI, Thrombolysis in Myocardial Infarction; MLD, Minimal
lumen diameter.
Data are presented as number of lesions (%) or mean± SD.
Table 3 Cumulative frequency of clinical outcomes at 30 days.
Clopidogrel (n = 159) Ticlopidine (n = 152) p
Death 0 (0) 2 (1.9) 0.50
Myocardial infarction 6 (3.8) 12 (7.9) 0.19
Q-wave myocardial infarction 1 (0.6) 0 (0)
Target vessel revascularization 1 (0.6) 1 (0.7) 0.68
Stent thrombosis 1 (0.6) 1 (0.7) 0.68
Major bleeding 7 (4.4) 6 (3.9) 0.94
Intracranial bleeding 0 (0) 0 (0)
Retroperitoneal bleeding 0 (0) 0 (0)
Hemoglobin decrease 3 g/dl with overt source 6 (3.8) 5 (3.3) 0.94
Hemoglobin decrease 4 g/dl without overt source 1 (0.6) 1 (0.7) 0.68
Blood transfusion 4 (2.5) 4 (2.6) 0.82
Composite of death, myocardial infarction, or target vessel
revascularization
6 (3.8) 13 (8.6) 0.13
Quadruple end point 13 (8.2) 18 (11.8) 0.37
Data are presented as number of patients (%).
Quadruple end point: composite of death, myocardial infarction, target vessel revascularization, or major bleeding
38 F. Hayashi et al.
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Migure 1 The 30-day incidence of myocardial infarction amo
he 30-day incidence of major bleeding among patients with un
urrently approved clopidogrel and ticlopidine at 30 days
fter stent implantation. (2) In patients with unstable
ngina, however, pretreatment with 300-mg loading dose
f clopidogrel therapy reduced the incidence of myocardial
nfarction during 30 days. Whereas the 300-mg loading dose
f clopidogrel was not associated with the increased risk of
ajor bleeding as compared with ticlopidine treatment.
Thienopyridine compounds, clopidogrel and ticlopidine,
re a potent and speciﬁc inhibitor of P2Y12 receptor of
latelet adenosine diphosphate (ADP) receptors, reducing
DP-induced platelet activation and aggregation. Although
iclopidine has been used conventionally in dual antiplatelet
herapy for patients undergoing stent implantation, an
mportant limitation is its delayed onset of action, with
aximum inhibition of ADP-induced platelet aggregation
chieved only several days after administration [6,7]. The
apid inhibition of platelet aggregation is crucial for the
revention of thrombotic complications after PCI, because
he occurrence of myocardial infarction in the early inva-
ive strategy is highest in the ﬁrst few days after procedures
9,10]. In patients with unstable angina pectoris and urgent
CI, we found an almost one-third incidence of myocardial
nfarction in patients treated with 300mg loading dose of
lopidogrel as compared to those treated with ticlopidine,
lthough the difference was not statistically signiﬁcant. The
eri-procedural myocardial infarction was largely non-Q-
p
d
T
d
ratients with unstable angina and urgent intervention (upper).
le angina and urgent intervention (bottom).
ave myocardial infarction. Clopidogrel has an advantage
f achieving the rapid and maximal inhibition of platelet
ggregation depending on the dose used. An experimen-
al ex vivo study has shown that it takes 3—6h to achieve
he maximal antiplatelet beneﬁt of clopidogrel following a
00mg loading dose [11]. Our ﬁnding is in line with previous
tudies that high-risk patients such as those with unstable
ngina derive beneﬁt from the pretreatment of 300mg load-
ng dose of clopidogrel [6,7]. The underlying mechanisms for
eneﬁcial effects of clopidogrel loading may be diminished
hrombus formation, distal embolization of platelet aggre-
ates, and side branch occlusion of thrombus during the
rocedure [12,13]. The positive effects of a 600mg clopi-
ogrel loading dose have been reported from many studies
14—16]. Müller et al. reported that administration of 600mg
lopidogrel accelerates inhibition of ADP-induced platelet
ggregation during the ﬁrst few hours to a level that can-
ot be accomplished by the conventional dosing regimen of
00mg clopidogrel before 48 h after ﬁrst drug administration
14]. The ARMYDA-2 (Antiplatelet Therapy for Reduction of
yocardial Damage During Angioplasty) study directly com-
ared the safety and efﬁcacy of 600mg clopidogrel loading
ose to 300mg loading dose in patients undergoing PCI [15].
he study demonstrated that the composite endpoint of 30-
ay major adverse cardiac events occurred in 4% of patients
eceiving 600mg and 12% of patients receiving 300mg
t
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(p = 0.04) and was due to differences in peri-procedural
myocardial infarction. Interestingly, our study showed, in
patients treated with 300mg loading dose of clopidogrel,
that the rate of myocardial infarction was 4.1%. That event
rate of our patients receiving 300mg is similar to those
receiving 600mg in the ARMYDA-2 study. That ﬁnding might
suggest that in the Japanese population, a 600mg loading
dose of clopidogrel is associated with no more clinical ben-
eﬁt. Therefore, there is still room to discuss introducing a
routine pretreatment with 600mg loading dose of clopido-
grel among Japanese patients.
An aggressive antithrombotic and antiplatelet treat-
ment strategy has been associated with an increased risk
of bleeding and requirement for blood transfusion [3,4].
Recent ﬁndings suggest that both myocardial infarction
and bleeding occurring after the procedure have compara-
ble prognostic value in predicting 1-year mortality [17,18].
Hence, a composite quadruple end point that includes
30-day incidence of death, myocardial infarction, urgent
revascularization, and major bleeding has recently been
proposed to assess the outcomes of patients undergoing PCI.
Kinnaird et al. have demonstrated that, in a retrospective
analysis of over 10 000 patients undergoing PCI at a sin-
gle center, major bleeding occurred in 5.4% of patients [4].
Similarly, in an analysis of over 24 000 patients with acute
coronary syndromes enrolled in the Global Registry of Acute
Coronary Events (GRACE), major bleeding occurred in 5.5%
of patients undergoing PCI [19]. When we looked at the per-
centages of major bleeding in our clopidogrel groups (4.4%
in all patients and 1.4% in patients receiving 300mg loading
dose), the event rates were lower than those of previous
studies, although a glycoprotein IIb/IIIa inhibitor was fre-
quently used in those studies. Intuitively, one might think
that in the Japanese population, the 300mg loading dose
of clopidogrel may be associated with an increased risk of
bleeding complications. In the era of ticlopidine, Japanese
patients undergoing stent implantation have been treated
with ticlopidine at a lower dose compared to the loading
and maintenance doses of ticlopidine in western countries.
However, the present study showed no signiﬁcant differ-
ence between clopidogrel and ticlopidine treatments, even
if the patients were treated with 300mg loading dose of
clopidogrel. Notably, we did not ﬁnd any serious bleed-
ing complications such as intracranial and retroperitoneal
bleeding. The present analyses should be interpreted with
caution because of the non-randomized design, relatively
small population, and data from a single center. In patients
with clopidogrel loading dose of 300mg, clopidogrel resis-
tance and ‘‘clopidogrel loading to needle time’’ are not
represented in this study. Furthermore, the drug-eluting
stent, which is of concern due to stent thrombosis were
used in 88% of our patients [20,21]. In addition, the use
of sirolimus- and paclitaxel-eluting stents was different
between the clopidogrel and ticlopidine groups. Therefore,
longer follow-up data are needed to address the net clinical
beneﬁt and timing of clopidogrel interruption.
In conclusion, we have demonstrated that in Japanese
clinical practice, clopidogrel treatment is feasible, and
the safety and efﬁcacy data are similar to those of ticlo-
pidine treatment. In patients with unstable angina and
emergent coronary intervention, adjunctive 300-mg load-
ing dose of clopidogrel may have a slight positive impact on39
he prevention of procedural myocardial infarction. Accrue-
ent of potential clinical advantage will require further
nvestigation.
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